Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
Nasdaq21d
Trinity Biotech Appoints Barclays Capital as Exclusive Financial Advisor to Advance Continuous Glucose Monitoring Technology Transformation Plan
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
Nasdaq1mon
Trinity Biotech Secures Additional $4 Million in Debt Financing to Advance Continuous Glucose Monitoring Technology and Transformation Plan
Following positive pre-pivotal trial results, Trinity Biotech is concentrating on its CGM technology while pursuing operational efficiencies to strengthen its financial position. The press release ...
Business Insider21d
Trinity Biotech engages Barclays to advise on strategic realignment process
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
Trinity Biotech (TRIB) Expected to Announce Quarterly Earnings on Thursday
Trinity Biotech (NASDAQ:TRIB – Get Free Report) will likely be announcing its earnings results before the market opens on ...
Hosted on MSN20d
Trinity Biotech receives non-compliance notice from Nasdaq
Trinity Biotech (TRIB) received notice from the Nasdaq Stock Market LLC that the company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a ...
Yahoo Finance21d
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring – Appoints Barclays to Advise on Ongoing Strategic Realignment Process
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech’s board and management have determined that CGM technology and ...
manilatimes22d
Trinity Biotech Further Strengthens Focus on Continuous Glucose Monitoring - Appoints Barclays to Advise on Ongoing Strategic Realignment Process
With substantial progress in developing its differentiated and innovative CGM and its significant market potential, Trinity Biotech's board and management have determined that CGM technology and ...